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Parkinson’s disease is a common progressive neurodegenerative disorder which mostly 
affects the elderly population, with a prevalence of more than 1.5% in the population 
over the age of 65 years. Clinical motor symptoms are mainly caused by degeneration of 
dopamine neurons in substantia nigra pars compacta. In order to identify genes with 
potential roles in the pathology of Parkinson’s disease, the candidate gene approach has 
been applied. Investigated genes assumed to play a role in mitochondrial maintenance 
were DJ-1, PTEN-induced putative kinase 1 (PINK1), the serine-protease OMI/HTRA2, 
mitochondrial translation initiation factor 3 (MTIF3), DNA polymerase gamma 1 
(POLG1), mitochondrial Ras homolog gene family, member T1 and T2 (MIRO1, 
MIRO2). Genes involved in detoxification including paraoxonases (PON1, PON2, 
PON3) and alcohol dehydrogenases (ADH1C, ADH4) were also studied. Association 
studies were performed in a Swedish case-control material consisting of 619 Parkinson 
patients and 1564 neurologically healthy controls. The screening resulted in 
identification of  several potential risk or protective factors such as DJ-1 Ala167Ala 
(c.501A>G), MTIF3 rs7669 (C>T), POLG1 CAG repeat variability and PON1 rs854571 
(G>A). MIRO1 and MIRO2 need further investigations before they can be excluded as 
contributing factors. The investigation of OMI/HTRA2 A141S (G>T) in Parkinson and 
Alzheimer patients resulted in an association with Alzheimer’s disease. In situ  
hybridization of human postmortem brain tissue was used to detect any alteration of 
PINK1 mRNA expression in Parkinson patients and of OMI/HTRA2 mRNA in patients 
with either Parkinson’s or Alzhemier’s disease. No differences compared to control 
levels were observed for the two genes. Protein quantification of OMI/HTRA2 in frontal 
cortex indicated reduced levels of the active enzyme form and increased protease activity 
in patients with Alzheimer’s disease. Using quantitative real-time PCR we detected a 
reduction of mRNA expression from the MTIF3 rs7669 minor allele. Based on previous 
report on association of genetic variants in ADH1C and ADH4 with Parkinson’s disease, 
we studied spontaneous and drug induced locomotor behavior in Adh1 and Adh4 
knockout mice, and in Adh1/4 double knockout mice with respect to dopamine-system-
related activity and olfactory function. Neurotransmitter levels were analyzed with high-
performance liquid chromatography in different brain regions. All three knockout strains 
displayed increased drug induced behavior, as well as alteration of levels of monoamines 
and their metabolites compared to wild-type littermates. Adh4-/- mice had a reduced 
sense of smell as well as reduction of dopamine in the olfactory bulb, and results from 
Adh1/4-/- pointed in the same direction. In conclusion, the findings presented in this 
thesis suggest genetic variability has an important role in the pathogenesis of Parkinson’s 
disease. The disease is a multifactorial and genetically complex disorder for which the 
etiology is unknown in most of the cases. It needs to be resolved how different molecular 
pathways involving different genes individually or together, contribute to disease by 
causing degeneration of dopamine neurons and other neuron types. 
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